Business · 1 sources covering this

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

Zydus' innovation portfolio is also emerging as a meaningful growth driver in the US. The innovative products contribute around 10% of the company's US revenue and remain highly profitable.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·1h ago
Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why
Zydus' innovation portfolio is also emerging as a meaningful growth driver in the US. The innovative products contribute around 10% of the company's US revenue and remain highly profitable.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/0641b6f9d744296002b0c27a0f41416ce5dbfabb"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why"></iframe>

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

How 1 sources are covering this

Zydus Lifesciences Share Price In Focus After Macquarie Maintains Outperform Rating. Here's Why

More from Business

Deadly Nepal Flood Kills at Least 162 With India on Alert

83 carat diamonds and a ‘naked dress’: Aryna Sabalenka’s daring US Open fashion statement explained

In ten months, Japan invested Rs 1 lakh cr out of Rs 7 lakh cr targeted for 10 yrs: Goyal

HAL, Samtel open India's first public-private defence avionics facility

Reader

Trust & legal

Across the network